The Duke Cancer Institute (DCI) wants to assure our patients that the safety of our patients, their loved ones, our team members and the community at large remains our highest priority. We are closely monitoring this rapidly evolving situation and are implementing all necessary precautions to prevent the spread of infection.

For the latest information about how we are keeping our community safe, please visit www.dukehealth.org.

What is Involved?

Part 1 is looking for the best dose of a study drug called NC-6300 for people with solid tumors.

Part 2 will look at the activity and safety of the drug when combined with Olaratumab in patients with soft tissue sarcoma.

In Part 1, patients will receive an intravenous infusion of NC-6300 on day 1 of each 21-day cycle until they have bad side effects or their disease gets worse.

In Part 2, patients will receive the best dose identified in Part 1 on day 1 of each 21 day cycle plus Olaratumuab on days 1 and 8 of each cycle until they have bad side effects or their disease gets worse.

All patients will go through a screening period with physical exams, testing and questionnaires.

While receiving the study drug, all patients will have testing on days 1, 8 and 15 of each cycle.

Patients in Part 1 will also have several blood tests throughout the day on day 1 of each cycle.